Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD vs RCD in Newly Diagnosed Waldenström Macroglobulinemia
NCT02844322Phase 4Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2016
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bortezomib, rituximab in Waldenström macroglobulinemia (WM), sponsored by Institute of Hematology and Blood Diseases Hospital. Started May 2016; status: completed.
02
Drugs
bortezomibrituximab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02844322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02844322.